Two doctors and co-founders of Fullerton Healthcare Corporation have been penalised with combined fines of S$160,000 following their guilty pleas to charges involving falsified entertainment claims that totalled over S$211,000. Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52 years old, did not personally benefit from the scheme. Rather, the inflated amounts were arranged to provide financial assistance to Collin Chiew, a 58-year-old former chief executive of insurance broker Aon Singapore, whose own legal proceedings remain unresolved.
Chan received the heavier fine of S$135,000 after admitting to five counts of falsification of accounts on July 10. The charges against him involved entertainment claims totalling over S$336,000 when actual expenses amounted to approximately S$125,000, resulting in an inflated discrepancy exceeding S$211,000. Tan, meanwhile, was fined S$25,000 after pleading guilty to a single count of falsification of accounts. His case involved a false claim of around S$82,000 against actual expenses of just over S$42,000, producing an inflated sum of nearly S$40,000 that formed part of the broader scheme involving Chan.
The court records reveal a coordinated operation centred on KTV entertainment receipts. Beginning in 2015, when Chiew reportedly requested financial assistance from Chan citing personal needs for his children and household expenses, the pair devised a system to generate inflated claims. During Chan's regular business trips to Hong Kong—occurring approximately twice monthly to support FHC's operations there—he would request false or exaggerated KTV receipts from David Sin, a third co-founder. These receipts were prepared by Tei Chu Pink, 46, who appears to have played a crucial role in the document fabrication scheme. Chan would subsequently collect the inflated receipts after ostensibly socialising at karaoke venues with Sin and Tei while meeting potential investors.
The mechanics of the scheme involved deliberate underreporting or non-payment at the entertainment venues themselves. On numerous occasions, Chan paid substantially reduced amounts using personal cash or credit cards, or in some instances made no payment whatsoever, yet would later claim full amounts based on the inflated receipts provided by Tei. Once returning to Singapore, Chan arranged for these documents to be distributed to designated personnel within FHC and its subsidiary Fullerton Health China, who would then process them through company financial systems to obtain funds. Multiple instances of these fraudulent claims proceeded with Tan's knowledge and involvement, indicating systematic rather than isolated misconduct.
The background to this arrangement provides important context for understanding the operation. Tan and Chan established Fullerton Healthcare Group in 2010 as a healthcare services provider operating through a network of doctors and specialists while assisting clients with insurance claim processing. Around 2012, during a business development phase, they became acquainted with Chiew through professional introductions. When Chiew approached Chan in 2015 requesting financial help, the two co-founders apparently decided that fabricating entertainment expenses offered a discreet mechanism to funnel money to him rather than providing direct assistance. This approach suggests an awareness of the impropriety of their actions and a deliberate effort to obscure the true nature of the transfers.
Notably, the prosecution applied for and obtained a discharge not amounting to an acquittal for all corruption-related charges against both men. District Judge Paul Quan approved this application on July 10, a procedural mechanism that effectively nullifies the immediate charges while preserving the theoretical possibility of future prosecution should additional evidence emerge. This decision indicates prosecutorial discretion in determining that pursuing corruption charges was not warranted, despite the clear intentional falsification of records.
The resolution contrasts with the handling of David Sin, the third FHC co-founder, who in August 2025 pleaded guilty to six counts of falsification of accounts and received an identical S$160,000 fine. Sin's conviction underscores the widespread nature of the scheme across the company's leadership hierarchy. The court documents confirm that Tan served as a director of Fullerton Healthcare Group during the relevant period, while Chan held the position of president of Fullerton Health China, another FHC subsidiary. Both men have since relinquished these roles, though the timing of their departures remains unspecified in available records.
The case raises significant questions about corporate governance and internal controls at Fullerton Healthcare. The involvement of three co-founders in falsifying financial records suggests systemic weaknesses in accountability mechanisms and audit procedures. For Malaysian readers, this scandal serves as a cautionary tale about the risks posed by unchecked authority among founding team members who may lack adequate external oversight. The scheme's operation across international jurisdictions, involving Hong Kong and Singapore operations, also highlights how multinational healthcare organisations can become vulnerable to cross-border financial fraud when proper controls are not implemented.
The pending status of Chiew's case introduces additional uncertainty into the proceedings. While documents do not confirm whether he actually received any of the inflated amounts, his position as a former senior executive at Aon Singapore—a major regional insurance broker—suggests he possessed sufficient financial sophistication to understand the nature of the arrangement. The fact that the falsified claims totalling over S$211,000 were specifically designed to benefit him raises questions about whether Chiew will face complementary charges or whether prosecutorial discretion will extend to him as well.
This enforcement action reflects Singapore's ongoing commitment to combating financial fraud within private sector organisations. The fines, while substantial, represent relatively modest penalties relative to the amounts falsified, potentially raising questions about whether they constitute sufficient deterrence. For Southeast Asian healthcare and insurance sectors, the case underscores the necessity for robust governance frameworks, particularly in organisations where founding members retain significant operational control. The involvement of multiple officers in the scheme demonstrates how individual misconduct can become systematised when internal checks prove inadequate.
Looking forward, the resolution of Chiew's pending case will likely provide clarification on prosecutorial attitudes toward individuals who benefit from such schemes without directly participating in the document falsification. The outcomes may also influence how regional regulators assess corporate governance practices within multinational health service providers operating across borders, a matter of increasing importance as Southeast Asian healthcare markets continue their rapid expansion and internationalisation.
